Debt-to-equity of InMed Pharmaceuticals Inc. from 31 Mar 2021 to 30 Sep 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
InMed Pharmaceuticals Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2021 to 30 Sep 2025.
  • InMed Pharmaceuticals Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 22%.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

InMed Pharmaceuticals Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 22% 30 Sep 2025
Q2 2025 25% 30 Jun 2025
Q1 2025 30% 31 Mar 2025
Q4 2023 30% -2% -7.4% 31 Dec 2023
Q3 2023 28% -10% -25% 30 Sep 2023
Q2 2023 21% -11% -33% 30 Jun 2023
Q1 2023 26% -4% -13% 31 Mar 2023
Q4 2022 32% +7% +29% 31 Dec 2022
Q3 2022 38% +12% +45% 30 Sep 2022
Q2 2022 32% -4% -11% 30 Jun 2022
Q1 2022 30% -6% -16% 31 Mar 2022
Q4 2021 25% 31 Dec 2021
Q3 2021 26% 30 Sep 2021
Q2 2021 35% 30 Jun 2021
Q1 2021 36% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.